Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $87.43.
RARE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Barclays reduced their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Wedbush increased their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th.
View Our Latest Research Report on RARE
Ultragenyx Pharmaceutical Stock Down 2.5 %
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The business had revenue of $147.03 million during the quarter, compared to analyst estimates of $123.20 million. During the same quarter last year, the company posted ($2.25) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 35.7% on a year-over-year basis. Equities analysts predict that Ultragenyx Pharmaceutical will post -6.24 earnings per share for the current year.
Insider Transactions at Ultragenyx Pharmaceutical
In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 40,091 shares of company stock valued at $2,125,513 in the last three months. Corporate insiders own 5.80% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. increased its holdings in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 352 shares during the last quarter. US Bancorp DE grew its holdings in Ultragenyx Pharmaceutical by 5.8% in the 1st quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 390 shares during the last quarter. Arizona State Retirement System grew its holdings in Ultragenyx Pharmaceutical by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 434 shares during the last quarter. ProShare Advisors LLC grew its holdings in Ultragenyx Pharmaceutical by 8.7% in the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 486 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at approximately $28,000. Institutional investors and hedge funds own 97.67% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Further Reading
- Five stocks we like better than Ultragenyx Pharmaceutical
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Are Penny Stocks a Good Fit for Your Portfolio?
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.